|
|
|
|
|
16.09.26 - 00:12
|
Turbett Surgical Appoints Jennifer Scalise-Mullett as Vice President, Quality, Regulatory, and Compliance (Business Wire)
|
|
|
HENRIETTA, N.Y.--(BUSINESS WIRE)--Turbett Surgical, a leader in innovative sterilization and operating room efficiency solutions, today announced the appointment of Jennifer Scalise-Mullett, J.D. as the company's new Vice President, Quality, Regulatory and Compliance.
In this strategic executive role, Scalise-Mullett will oversee all global regulatory affairs, quality assurance, and compliance activities. She will provide executive guidance on quality, regulatory, and compliance matters that inform business strategy, operational decision-making, and organizational growth. Her leadership will support Turbett Surgical's ongoing expansion and the commercialization of its advanced multi-tray sterilization systems, ensuring the highest standards of product quality, patient safety and regulatory compliance.
Scalise-Mullett brings over two decades of experience in the medical device, biotechnology, and pharmaceutical industries, having held leadership roles with organizations including Fresenius, Biogen Idec, ...
|
|
|
|
|
|
|
|
|
|
|
|
|
26.08.26 - 11:21
|
Biogen Aktie: Vor dem Milliarden-Durchbruch? Diese Studiendaten könnten den Aktienkurs befeuern! (Aktiencheck)
|
|
|
CambridgeToronto (www.aktiencheck.de) - Biogen-Aktienanalyse von RBC Capital Markets:
RBC Capital habe das Kursziel für die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP, NASDAQ-Symbol: BIIB) von 240 auf 260 USD erhöht und das Rating "outperform" bestätigt. Als nächsten mit großer Spannung erwarteten Kurstreiber für Biogen bezeichne man die für das vierte Quartal erwarteten Studiendaten zu Litifilimab. [mehr]...
|
|
|
25.08.26 - 13:15
|
Veeva Vault CRM Selected by Biogen (PR Newswire)
|
|
|
Unified commercial platform to help speed the delivery of medicines to patients PLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has committed to Veeva Vault CRM globally. "We are honored to provide Vault CRM as the agentic......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.07.26 - 14:33
|
Biogen Aktie: Entscheidende Lupus-Studie könnte den nächsten Kurstreiber liefern! (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - Biogen-Aktienanalyse von H.C. Wainwright & Co:
H.C. Wainwright & Co habe das Kursziel für die Aktie Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP, NASDAQ-Symbol: BIIB) von 237 auf 251 USD angehoben und das Rating "buy" bestätigt. Die Analysten hätten nach den starken Quartalsergebnissen ihre Annahmen zur Marktdurchdringung der Medikamente Leqembi, Spinraza und Tysabri überprüft und angepasst. [mehr]...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
